This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
July 29, 2013 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD) today announced that its central laboratory services once again ranked first in an independent global survey of physician investigators participating in clinical trials. Forty-seven percent of the study participants named Covance's central laboratory services as their "most preferred" central laboratory, with investigators citing Covance more than twice as often as the nearest competitor. Investigators also reported having the "best overall relationship" with Covance, rating it 8.4 on a scale of 1 to 10.
Survey results underscore the growing importance of the selection of a preferred central laboratory because of its direct connection to investigators' satisfaction and their willingness to work with sponsors in the future. In addition, most physicians who want to learn about being a clinical trial investigator talk first to other doctors involved in clinical trials.
"This study demonstrates that investigators around the world continue to recognize and value Covance's services and benefit from our decades of experience and extensive testing capabilities," said
Jon Koch, Corporate Vice President and Global General Manager, Central Laboratory Services. "Our ability to deliver central laboratory services on target and on time, coupled with our commitment to meeting the evolving needs of clients and investigators, is what makes Covance a leader in providing drug development services and helps our clients bring medicines to market faster."
The report shows a clear link between overall investigator satisfaction and sponsors' choice of central laboratory, with 100 percent of respondents reporting they were satisfied when pharmaceutical sponsors select the investigators' preferred central laboratory. When pharmaceutical sponsors select the investigators' least preferred central laboratory, satisfaction drops significantly. Respondents cited central laboratory preference as a key driver of satisfaction with the pharmaceutical sponsor as well, with 91 percent of investigators stating that they are more satisfied and willing to work with a sponsor on trials when sponsors have selected investigators' preferred central laboratory. Ninety-eight percent of investigators indicate the central laboratory selected by the sponsor impacts their success (and that of their staff), their day-to-day activities, and their willingness to work with a particular sponsor on future studies.